Dendreon Execs Sued Over Sunny Cancer Drug Sales Forecasts

Law360, New York (July 9, 2012, 6:22 PM EDT) -- Dendreon Corp.'s executives have been hit with a shareholder derivative suit accusing them of withholding details about marketing issues concerning the firm's prostate cancer drug Provenge and causing a 67 percent stock drop when those problems were revealed, according to court documents made public Monday.

In a redacted complaint filed in Delaware state court, investor Herbert Silverberg accused the directors and officers of the Seattle-based biotechnology firm of cashing in on their knowledge of internal corporate information about doctors’ reluctance to administer the drug, allegedly selling...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.